|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
CureLab, Inc., Canton Vaccine Firm, Plans North Dakota Move
12/17/2012 9:08:06 AM
Fargo biotechnology company Aldevron has been chosen to produce cancer vaccines being developed by a Boston-area research company that plans to move most of its operations to North Dakota. The DNA-based vaccines have shown promise in animal studies in suppressing lung and breast cancers, the Forum newspaper reported. CureLab Oncology will keep a lab and office in Canton, but plans to move most of its operations sometime next year to North Dakota, possibly to Fargo or Grand Forks, where it also is collaborating with Avianax, a biotech company at the University of North Dakota. The company will bring a few people to North Dakota but plans to hire local college and university graduates, CEO Alex Schneider said. ‘‘We already have put our foot on the soil,’’ Schneider said of the production partnership with Aldevron, which does custom DNA work for research labs around the world. The addition of CureLab to the area will help Fargo-Moorhead in its efforts to establish the area as a hub for the growing vaccine and biotech industries, said Michael Chambers, Aldevron’s chief executive.
|
|
|
|
|
|
|
|
|
|
|